

## Product datasheet for **TL303350**

### TAB1 Human shRNA Plasmid Kit (Locus ID 10454)

#### Product data:

|                           |   |
|---------------------------|---|
| Product Type:             | shRNA Plasmids  |
| Product Name:             | TAB1 Human shRNA Plasmid Kit (Locus ID 10454)   |
| Locus ID:                 | 10454   |
| Synonyms:                 | 3'-Tab1; MAP3K7IP1  |
| Vector:                   | pGFP-C-shLenti (TR30023)  |
| E. coli Selection:        | Chloramphenicol (34 ug/ml)  |
| Mammalian Cell Selection: | Puromycin   |
| Format:                   | Lentiviral plasmids   |
| Components:               | TAB1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 10454).<br>5µg purified plasmid DNA per construct<br>29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.   |
| RefSeq:                   | <a href="#">NM_006116</a> , <a href="#">NM_153497</a> , <a href="#">NM_006116.1</a> , <a href="#">NM_006116.2</a> , <a href="#">NM_153497.1</a> , <a href="#">NM_153497.2</a> , <a href="#">BC050554</a> , <a href="#">BC050554.1</a> , <a href="#">BC038582</a> , <a href="#">NM_153497.3</a> , <a href="#">NM_006116.3</a>  |
| UniProt ID:               | <a href="#">Q15750</a>  |
| Summary:                  | The protein encoded by this gene was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008] |
| shRNA Design:             | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .  |



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).